Literature DB >> 23959694

Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization.

Jianyong Lei, Wentao Wang, Lunan Yan.   

Abstract

AIMS: The aim of this study was to compare the effectiveness and safety of hepatic resection versus open-approach RFA (ORFA) for small hepatocellular carcinomas (HCC) within Milan criteria after successful downstaging therapy by transcatheter arterial chemoembolization.
MATERIAL AND METHODS: Between February 2005 and February 2008, a total of 110 patients with advanced HCC met the Milan criteria after successful downstaging therapy; 58 patients then underwent hepatic resection and 52 received ORFA. Outcomes, including short- and long-term morbidity, 1-, 3-, and 5-year mortality and HCC-free survival, were analyzed and compared between the two groups.
RESULTS: Patients in the hepatic resection and ORFA groups showed similar baseline characteristics and downstaging protocols. The ORFA group showed less blood loss, lower hospital costs, shorter surgical time, and fewer hospital stay days (P < 0.05). The 1-, 3-, and 5-year overall survival rates were 94.8, 86.2, and 79.3%, respectively, with liver resection and 96.2, 82.7, and 76.9% with ORFA (P=0.772). The 1-, 3-, and 5-year recurrence-free survival rates were 93.1, 81.0, and 77.6% with resection and 94.2, 76.9, and 73.1% with ORFA (P=0.705). The ORFA patients suffered fewer postoperative complications (P=0.09), particularly among the cases of central HCC (P=0.015).
CONCLUSION: Resection and ORFA achieved similar survival benefits in the management of HCC within Milan criteria after successful downstaging. The decreased blood loss, hospital costs, surgical time, and hospital stay days, and lower complication rates in central cases render ORFA a preferred treatment option.

Entities:  

Mesh:

Year:  2013        PMID: 23959694     DOI: 10.1007/s11605-013-2311-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  41 in total

1.  Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function.

Authors:  Sung Noh Hong; Sun-Young Lee; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee; Dongil Choi; Hyo Keun Lim; Kwang-Woong Lee; Jae Won Joh
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

2.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Francis Y Yao; Milan Kinkhabwala; Jeanne M LaBerge; Nathan M Bass; Robert Brown; Robert Kerlan; Alan Venook; Nancy L Ascher; Jean C Emond; John P Roberts
Journal:  Am J Transplant       Date:  2005-04       Impact factor: 8.086

Review 4.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

5.  The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996.

Authors:  W G Cance; A K Stewart; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

6.  Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation.

Authors:  Yasuji Komorizono; Makoto Oketani; Katsumi Sako; Naruhiro Yamasaki; Toshihiko Shibatou; Masahiko Maeda; Kazunori Kohara; Shuhou Shigenobu; Kazuaki Ishibashi; Terukatsu Arima
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

7.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

8.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.

Authors:  William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

10.  Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Authors:  Shinichi Ueno; Masahiko Sakoda; Fumitake Kubo; Kiyokazu Hiwatashi; Taro Tateno; Yoshiro Baba; Susumu Hasegawa; Hirohito Tsubouchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-03-20
View more
  4 in total

1.  Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE.

Authors:  L Jiang; J Y Lei; W T Wang; L N Yan; B Li; T F Wen; M Q Xu; J Y Yang; Y G Wei
Journal:  J Gastrointest Surg       Date:  2014-03-25       Impact factor: 3.452

2.  Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?

Authors:  Lei Jianyong; Yan Lunan; Wang Wentao; Zeng Yong; Li Bo; Wen Tianfu; Xu Minqing; Yang Jiaying
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

3.  Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas.

Authors:  Yanyan Wei; Yongxiang Yi; Chen Tao; Wei Ye; Wei Zhao
Journal:  Cancer Manag Res       Date:  2019-09-17       Impact factor: 3.989

4.  Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Ninggang Zheng; Xiaodong Wei; Dongzhi Zhang; Wenxiao Chai; Ming Che; Jiangye Wang; Binbin Du
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.